- Foghorn Therapeutics (FHTX, Financial) plans a virtual investor event on April 29, 2025.
- New preclinical data for FHD-909, a selective SMARCA2 inhibitor, will be presented.
- The event coincides with the 2025 AACR Annual Meeting.
Foghorn Therapeutics Inc. (NASDAQ: FHTX), a biopharmaceutical company focused on developing novel therapies, has announced a virtual investor event scheduled for April 29, 2025, at 8:00 a.m. ET. The event will align with the 2025 American Association for Cancer Research (AACR) Annual Meeting, which runs from April 25-30, 2025.
During the event, Foghorn will reveal new preclinical combination data for FHD-909 (LY4050784), a promising first-in-class selective SMARCA2 inhibitor targeting non-small cell lung cancer (NSCLC). This presentation will highlight significant progress in Foghorn's research and development efforts.
The company will also provide updates on its key programs, including the preclinical data for the Selective CBP degrader program, explored in tandem with chemotherapy and targeted agents, and the Selective EP300 degrader program in hematological malignancies. An overview of the Selective ARID1B degrader program will also be shared.
The webcast will be accessible through Foghorn's website, offering replay options post-event to allow wider access for interested investors and stakeholders. This initiative underscores Foghorn Therapeutics' commitment to transparent communication and innovation within the biotechnology sector.
